Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023
Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023
Abstract
Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023 Report Highlights:
• Global Anti TIGIT Antibodies Market Dynamics
• Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication
• Anti TIGIT Antibodies In Clinical Trials : > 45
• Overview On Partnerships & Collaborations In The Global Anti TIGIT Antibodies Market
• Global Anti TIGIT Antibodies Market Outlook
• Competitive Landscape
The advancement in the field of genomics has led to identification of T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) as a promising emerging immune checkpoint target. TIGIT indirectly suppresses T-cell activation and is expressed on multiple types of immune cells, including regulatory T (Treg) cells, activated T cells, and natural killer (NK) cells. TIGIT is up regulated in T cells and NK cells after ligand binding, inhibiting these cells’ ability to kill tumor cells. Increased TIGIT expression is also associated with advanced disease and poor survival outcomes. Additionally, increased TIGIT expression after treatment is associated with disease recurrence.
Since its identification as potential immunotherapy target, pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors and are reporting promising preclinical and clinical trial results. Recently, iTeos Therapeutics has announced promising preclinical and clinical analyses supporting the multifaceted mechanism of action of its anti-TIGIT antibody, EOS-448/GSK4428859A, which is being developed in collaboration with GlaxoSmithKline. Various combinations of anti-TIGIT antibody isotopes have been studied in cancer models of mouse. Depending on the isotope used, the preclinical analyses of these combinations have demonstrated different anti-tumor activities. Strong anti-tumor activities have been found while using the isotope engaging the FcγR, which has been linked to the activation of effector CD8 T cells and the reduction in the number of Treg cells in the tumor microenvironment. EOS-448 has further shown to induce the depletion of the precursors of exhausted T cells in addition to regulatory T cells, but not of stem-like memory T cells.
The recent years have seen an increase in collaborations and partnerships between companies for a faster development of novel drugs. Shanghai Junshi Biosciences and Coherus Bioscience recently announced that the two are taking their immuno-oncology collaboration agreement further by allowing Coherus to initiate its option to license the former’s potential anti-TIGIT antibody - JS 006 - in the US and China. Regulatory bodies of the two regions have already approved the drug’s Investigational new drug (IND) applications, allowing the companies to develop it further clinically. Apart from this, clinical trials are ongoing which are assessing the drug’s safety, pharmacokinetic properties and tolerability post dose escalation and expansion, as a monotherapy and in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors.
Apart from these trends in the market, the pipeline of novel TIGIT inhibitor is highly crowded which suggests promising future of the market. The key drugs in research and development include including AB 154, Ociperlimab, COM902, EOS448, Tiragolumab, and others. As per our analysis, TIGIT inhibitor is expected to enter the market by 2024, which will transform the overall immunotherapy market during the forecast period. However, the market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of majority regions is shifting towards novel therapeutic approach the drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years.
As per our report findings, the global market is expected to have opportunity of more than US$ 300 Million once the first Anti TIGIT antibody is commercially approved in coming years. The Anti TIGIT Antibody clinical development and market opportunity is driven by the rising occurrence of different forms of cancer, technological advancements in the field of immune-oncology for cancer treatment, and rising awareness concerning the benefits of targeted therapies over conventional cancer therapies. Apart from this, rising government initiatives, increasing awareness among population, and development of favorable reimbursement policies is also boosting the growth of market during the forecast period.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and other development activities.
Content
Table of Contents
1. Introduction to TIGIT Inhibitor
2. Role Of TIGIT Inhibitors By Indications
2.1 TIGIT Inhibitors in Cancer
2.2 TIGIT Inhibitors in HIV
2.3 TIGIT in Autoimmune Disorders
3. Mechanism of Anti TIGIT Antibodies
3.1 Overview
3.2 Clinical Approaches to Target TIGIT
4. Partnerships & Collaborations In The Global Anti TIGIT Antibodies Market
5. Global TIGIT inhibitors Clinical Trials Overview
5.1 By Company
5.2 By Country
5.3 By Indication
5.4 By Patient Segment
6. Global Anti TIGIT Antibody Clinical Pipeline By Company, Indication & Phase
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-III
7. FDA Orphan Designation for Tiragolumab
8. Global Anti TIGIT Antibody Market Dynamics
8. 1 Market Drivers
8. 2 Commercialization Challenges
9. Global TIGIT Inhibitor Market Future Outlook
10. Competitive Landscape
10.1 Arcus Biosciences
10.2 Agenus
10.3 Astellas Pharma
10.4 AstraZeneca
10.5 BeiGene
10.6 Bristol Myers Squibb
10.7 Compugen
10.8 Gilead Sciences
10.9 iTeos Therapeutics
10.10 Merck
10.11 Roche
10.12 Seagen
10.13 Shanghai Henlius Biotech
List of Figure
Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT & PD-1 Blockade
Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
Figure 2-4: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
Figure 2-5: TIGIT Associated Autoimmune Disorders
Figure 3-1: TIGIT Inhibitor – Proposed Mechanism of Action
Figure 3-2: TIGIT Inhibitor – Mechanism of Action
Figure 3-3: Binding Efficacy of Monoclonal Antibody
Figure 3-4: Binding Efficacy of Bispecific Antibodies
Figure 3-5: Advantages of Small Molecule Drugs over Therapeutic Antibodies
Figure 5-1: Global – Anti TIGIT Antibodies Clinical Trials by Company, 2023
Figure 5-2: Global – Anti TIGIT Antibodies Clinical Trials by Country, 2023
Figure 5-3: Global – Anti TIGIT Antibodies Clinical Trials By Indication, 2023
Figure 5-4: Global – Anti TIGIT Antibodies Clinical Trials by Patient Segment, 2023
Figure 7-1: Tiragolumab - SKYSCRAPER08 Phase-III Trial Initiation & Completion Year
Figure 8-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 8-2: Global – TIGIT Inhibitor Market Drivers
Figure 8-3: Stages of Drug Development
• Global Anti TIGIT Antibodies Market Dynamics
• Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication
• Anti TIGIT Antibodies In Clinical Trials : > 45
• Overview On Partnerships & Collaborations In The Global Anti TIGIT Antibodies Market
• Global Anti TIGIT Antibodies Market Outlook
• Competitive Landscape
The advancement in the field of genomics has led to identification of T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) as a promising emerging immune checkpoint target. TIGIT indirectly suppresses T-cell activation and is expressed on multiple types of immune cells, including regulatory T (Treg) cells, activated T cells, and natural killer (NK) cells. TIGIT is up regulated in T cells and NK cells after ligand binding, inhibiting these cells’ ability to kill tumor cells. Increased TIGIT expression is also associated with advanced disease and poor survival outcomes. Additionally, increased TIGIT expression after treatment is associated with disease recurrence.
Since its identification as potential immunotherapy target, pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors and are reporting promising preclinical and clinical trial results. Recently, iTeos Therapeutics has announced promising preclinical and clinical analyses supporting the multifaceted mechanism of action of its anti-TIGIT antibody, EOS-448/GSK4428859A, which is being developed in collaboration with GlaxoSmithKline. Various combinations of anti-TIGIT antibody isotopes have been studied in cancer models of mouse. Depending on the isotope used, the preclinical analyses of these combinations have demonstrated different anti-tumor activities. Strong anti-tumor activities have been found while using the isotope engaging the FcγR, which has been linked to the activation of effector CD8 T cells and the reduction in the number of Treg cells in the tumor microenvironment. EOS-448 has further shown to induce the depletion of the precursors of exhausted T cells in addition to regulatory T cells, but not of stem-like memory T cells.
The recent years have seen an increase in collaborations and partnerships between companies for a faster development of novel drugs. Shanghai Junshi Biosciences and Coherus Bioscience recently announced that the two are taking their immuno-oncology collaboration agreement further by allowing Coherus to initiate its option to license the former’s potential anti-TIGIT antibody - JS 006 - in the US and China. Regulatory bodies of the two regions have already approved the drug’s Investigational new drug (IND) applications, allowing the companies to develop it further clinically. Apart from this, clinical trials are ongoing which are assessing the drug’s safety, pharmacokinetic properties and tolerability post dose escalation and expansion, as a monotherapy and in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors.
Apart from these trends in the market, the pipeline of novel TIGIT inhibitor is highly crowded which suggests promising future of the market. The key drugs in research and development include including AB 154, Ociperlimab, COM902, EOS448, Tiragolumab, and others. As per our analysis, TIGIT inhibitor is expected to enter the market by 2024, which will transform the overall immunotherapy market during the forecast period. However, the market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of majority regions is shifting towards novel therapeutic approach the drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years.
As per our report findings, the global market is expected to have opportunity of more than US$ 300 Million once the first Anti TIGIT antibody is commercially approved in coming years. The Anti TIGIT Antibody clinical development and market opportunity is driven by the rising occurrence of different forms of cancer, technological advancements in the field of immune-oncology for cancer treatment, and rising awareness concerning the benefits of targeted therapies over conventional cancer therapies. Apart from this, rising government initiatives, increasing awareness among population, and development of favorable reimbursement policies is also boosting the growth of market during the forecast period.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and other development activities.
1. Introduction to TIGIT Inhibitor
2. Role Of TIGIT Inhibitors By Indications
2.1 TIGIT Inhibitors in Cancer
2.2 TIGIT Inhibitors in HIV
2.3 TIGIT in Autoimmune Disorders
3. Mechanism of Anti TIGIT Antibodies
3.1 Overview
3.2 Clinical Approaches to Target TIGIT
4. Partnerships & Collaborations In The Global Anti TIGIT Antibodies Market
5. Global TIGIT inhibitors Clinical Trials Overview
5.1 By Company
5.2 By Country
5.3 By Indication
5.4 By Patient Segment
6. Global Anti TIGIT Antibody Clinical Pipeline By Company, Indication & Phase
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-III
7. FDA Orphan Designation for Tiragolumab
8. Global Anti TIGIT Antibody Market Dynamics
8. 1 Market Drivers
8. 2 Commercialization Challenges
9. Global TIGIT Inhibitor Market Future Outlook
10. Competitive Landscape
10.1 Arcus Biosciences
10.2 Agenus
10.3 Astellas Pharma
10.4 AstraZeneca
10.5 BeiGene
10.6 Bristol Myers Squibb
10.7 Compugen
10.8 Gilead Sciences
10.9 iTeos Therapeutics
10.10 Merck
10.11 Roche
10.12 Seagen
10.13 Shanghai Henlius Biotech
List of Figure
Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT & PD-1 Blockade
Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
Figure 2-4: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
Figure 2-5: TIGIT Associated Autoimmune Disorders
Figure 3-1: TIGIT Inhibitor – Proposed Mechanism of Action
Figure 3-2: TIGIT Inhibitor – Mechanism of Action
Figure 3-3: Binding Efficacy of Monoclonal Antibody
Figure 3-4: Binding Efficacy of Bispecific Antibodies
Figure 3-5: Advantages of Small Molecule Drugs over Therapeutic Antibodies
Figure 5-1: Global – Anti TIGIT Antibodies Clinical Trials by Company, 2023
Figure 5-2: Global – Anti TIGIT Antibodies Clinical Trials by Country, 2023
Figure 5-3: Global – Anti TIGIT Antibodies Clinical Trials By Indication, 2023
Figure 5-4: Global – Anti TIGIT Antibodies Clinical Trials by Patient Segment, 2023
Figure 7-1: Tiragolumab - SKYSCRAPER08 Phase-III Trial Initiation & Completion Year
Figure 8-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 8-2: Global – TIGIT Inhibitor Market Drivers
Figure 8-3: Stages of Drug Development
Related Report
